Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent

Lorena Lazo de la Vega1, Daniel H Hovelson2, Andi K Cani1

  • 1Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.

Human Pathology
|September 25, 2016
PubMed

Insights

Next-generation sequencing revealed limited somatic mutations in CIC-DUX4 sarcomas. However, novel copy number alterations, including chromosome 1p loss, were identified, offering new insights into soft tissue sarcoma drivers.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • CIC-DUX4 sarcomas are rare soft tissue tumors with poorly understood molecular drivers.
  • Recurrent alterations like chromosome 8 trisomy are known, but other genetic changes remain largely unidentified.

Purpose of the Study:

  • To characterize potential somatic driver alterations in CIC-DUX4 sarcomas using next-generation sequencing.
  • To identify novel genetic alterations beyond known chromosomal abnormalities.

Main Methods:

  • Targeted next-generation sequencing of 409 genes in 11 CIC-DUX4 sarcoma samples.
  • Analysis included copy number profiling and mutation detection.
  • Comparison of matched primary and recurrence/metastasis samples.

Main Results:

  • No recurrent somatic mutations (point mutations, indels) were found.
  • Recurrent broad copy number alterations, including chromosome 8 gain and 1p loss, were identified.
  • A somatic ARID1A nonsense mutation was found in a local recurrence sample; chromosome 7q loss was observed post-radiation.

Conclusions:

  • Next-generation sequencing identified limited somatic driver mutations in CIC-DUX4 sarcomas.
  • Novel recurrent copy number alterations, notably chromosome 1p loss (ARID1A locus), were discovered.
  • Further research is needed to elucidate the biological and clinical impact of these findings.